Bioventus (BVS) Total Debt Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 157.11% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -12.26% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 5.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -2.48% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.12% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 8.70% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 15.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -5.48% |
| 10 | Bioventus | 535.01 Mn | 544.52 Mn | 90.77 Mn | -14.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -14.75% |
| Dec 31, 2025 | -10.34% |
| Sep 27, 2025 | -11.44% |
| Jun 28, 2025 | -6.11% |
| Mar 29, 2025 | -18.42% |
| Dec 31, 2024 | -10.66% |
| Sep 28, 2024 | -7.70% |
| Jun 29, 2024 | -5.81% |
| Mar 30, 2024 | -12.20% |
| Dec 31, 2023 | -12.22% |
| Sep 30, 2023 | -7.02% |
| Jul 1, 2023 | 3.18% |
| Apr 1, 2023 | 20.97% |
| Dec 31, 2022 | 16.88% |
| Oct 1, 2022 | 139.19% |
| Jul 2, 2022 | 106.52% |
| Apr 2, 2022 | 101.51% |
| Dec 31, 2021 | 89.87% |